Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 Fast-growings companies in Ribociclib
by Most Patent Filing In 1 Year in the world in 2022

The Ribociclib top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 1 Year Ribociclib Fast-growings in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Guizhou Sheng, China
Patent: 1
2
United States
Patent: 1
3
China
Patent: 1
4
Biotx Ai GmbH
Germany
Patent: 1
5
Zhejiang Sheng, China
Pinyin,Mainland China,Chemistry,
...[+2]
Patent: 1
Page generation time: Jul 07 2025